Document 0153
 DOCN  M95B0153
 TI    Antiviral therapy for human immunodeficiency virus infections.
 DT    9511
 AU    De Clercq E; Rega Institute for Medical Research, Katholieke
       Universiteit; Leuven, Belgium.
 SO    Clin Microbiol Rev. 1995 Apr;8(2):200-39. Unique Identifier : AIDSLINE
       MED/95346869
 AB    Depending on the stage of their intervention with the viral replicative
       cycle, human immunodeficiency virus inhibitors could be divided into the
       following groups: (i) adsorption inhibitors (i.e., CD4 constructs,
       polysulfates, polysulfonates, polycarboxylates, and polyoxometalates),
       (ii) fusion inhibitors (i.e., plant lectins, succinylated or
       aconitylated albumins, and betulinic acid derivatives), (iii) uncoating
       inhibitors (i.e., bicyclams), (iv) reverse transcription inhibitors
       acting either competitively with the substrate binding site (i.e.,
       dideoxynucleoside analogs and acyclic nucleoside phosphonates) or
       allosterically with a nonsubstrate binding site (i.e., non-nucleoside
       reverse transcriptase inhibitors), (v) integration inhibitors, (vi) DNA
       replication inhibitors, (vii) transcription inhibitors (i.e., antisense
       oligodeoxynucleotides and Tat antagonists), (viii) translation
       inhibitors (i.e., antisense oligodeoxynucleotides and ribozymes), (ix)
       maturation inhibitors (i.e., protease inhibitors, myristoylation
       inhibitors, and glycosylation inhibitors), and finally, (x) budding
       (assembly/release) inhibitors. Current knowledge, including the
       therapeutic potential, of these various inhibitors is discussed. In view
       of their potential clinical the utility, the problem of virus-drug
       resistance and possible strategies to circumvent this problem are also
       addressed.
 DE    Antiviral Agents/CHEMISTRY/PHARMACOLOGY/*THERAPEUTIC USE  Base Sequence
       Drug Resistance, Microbial  Drug Therapy, Combination  Human  HIV/DRUG
       EFFECTS/PHYSIOLOGY  HIV Infections/*DRUG THERAPY/VIROLOGY  Molecular
       Sequence Data  Reverse Transcriptase/ANTAGONISTS & INHIB  Support,
       Non-U.S. Gov't  Virus Integration/DRUG EFFECTS  Virus Replication/DRUG
       EFFECTS  JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).